Abstract

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3

Author(s): Zur Eyal

Issue: Sep/Oct 2019 - Volume 23, Number 5

Page(s): 366-375

Download in electronic PDF format for $75
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 1
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 2
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 3
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 4
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 5
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 6
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 7
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 8
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 9
  • Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 10

Abstract

Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.

Related Keywords

  • cutaneous leishmaniasis
  • leishmania major
  • leishmania tropica
  • Israel
  • topical preparations
  • photodynamic therapy
  • daylight activation
  • photosensitizer
  • 5-aminolevulinic acid hydrochloride
  • formulations
  • amphotericin B liposomal gel
  • paromomycin sulfate liposomal gel

Related Categories

  • DERMATOLOGY
  • EXCIPIENTS
  • FORMULATIONS
  • DOSAGE FORMS/DRUG CARRIERS
  • INFECTIOUS DISEASE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2019
Pg. 366-375
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Author(s): Zur Eyal
Jul/Aug 2019
Pg. 288-293
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Author(s): Zur Eyal
May/Jun 2019
Pg. 200-207
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Author(s): Zur Eyal
Jul/Aug 2003
Pg. 266-270
Sensitization Therapy for Warts
Author(s): Kuntz Rachael
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
May/Jun 2009
Pg. 262-263
PostScription: Compounding in Israel
Author(s): Zur Eyal
Nov/Dec 2018
Pg. 446-454
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Author(s): Zur Eyal
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Jul/Aug 1999
Pg. 309-310
Acidifying Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Nov/Dec 2011
Pg. 458-463
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Author(s): Zur Eyal
Jan/Feb 2019
Pg. 23-31
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Author(s): Zur Eyal
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Sep/Oct 2004
Pg. 354-357
Current Topical Treatments in Wound Healing - Part 2
Author(s): Helmke Christopher D
Mar/Apr 2019
Pg. 94-104
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Author(s): Zur Eyal
Nov/Dec 2022
Pg. 480-488
A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Author(s): Riepl Mike
May/Jun 2003
Pg. 176-178
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Author(s): Israel Alan
Sep/Oct 2022
Pg. 423
Ascorbic acid 5% Topical Microemulsion
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 410
Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion
Author(s): Allen Loyd V Jr
May/Jun 2015
Pg. 243
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Author(s): Allen Loyd V Jr